Raw Steroid Powders Raloxifene Hydrochloride 82640 - 04 - 8 Prevention Of Osteoporosis

Detailed Product Description

Raloxifene (marketed as Evista by Eli Lilly and Company) is an oral selective estrogen receptor modulator (SERM) that has estrogenic actions on bone and anti-estrogenic actions on the uterus and breast. It is used in the prevention of osteoporosis in postmenopausal women.

Raloxifene hydrochloride-- Quick Detail :

Raloxifene hydrochloride -- Raloxifene hydrochloride

Raloxifene hydrochloride -- Alias: Raloxifene HCL;KEOXIFENE;AKOS 92138

Raloxifene hydrochloride -- CAS Registry Number:82640-04-8

Raloxifene hydrochloride -- Purity: 99%

Raloxifene hydrochloride -- MF: C28H28ClNO4S

Raloxifene hydrochloride -- MW: 510.04

Raloxifene hydrochloride -- Appearance:light yellow powder

Raloxifene hydrochloride -- Related Substances : Pharmaceutical Grade

Raloxifene hydrochloride -- Storage: Shading, confined preservation

Raloxifene hydrochloride -- Usage :It is used in the prevention of osteoporosis in postmenopausal women.

Skype:sucy1171

E -mail:pharmacy@ycgmp.com

Whatsapp:+8618565342920

Raloxifene hydrochloride-- Description:

Evista is Eli Lilly & Companys brand name for raloxifen hydrochloride, a second-generation Selective Estrogen Receptor Modulator (SERM) in the Raloxifene hydrochloridebenzothiophene family. On September 13, 2007, the U. S. Food and Drug Raloxifene hydrochloride Administration approved Evista for reduction in the risk of invasive breast cancer in postmenopausal women with and Raloxifene hydrochloride without osteoporosis. It has also been approved as a potent stand-alone osteoporosis treatment.Raloxifene hydrochloride

Raloxifene hydrochloride-- Applications:

Raloxi